Major structural component of hydroxyapatite [Ca10(PO4)6(OH)2] in bone and tooth mineral matrix (~85% of body phosphorus)
Backbone of DNA and RNA phosphate-sugar polymers
Essential structural component of phospholipids (phosphatidylcholine, phosphatidylethanolamine, etc.) forming all cellular membranes
High-energy phosphoanhydride bonds in ATP/ADP/AMP and creatine phosphate transfer cellular energy
Phosphorylation/dephosphorylation of proteins (kinase/phosphatase cascades) controls major signaling pathways
Molecular + tissue targets
Bone and tooth mineralization (hydroxyapatite matrix)
Cellular membrane phospholipid bilayers
Energy metabolism (ATP / phosphocreatine systems)
Nucleic acid synthesis and structural integrity
Acid-base buffering (phosphate buffer in blood and intracellular)
Dosage range
US IOM RDA: 700 mg/day adults 19+. EFSA NDA AI: 550 mg/day adults. EFSA NRV (labelling): 700 mg. US IOM Tolerable Upper Intake Level (UL): 4000 mg/day adults 19-70y (3000 mg/day 70+). EFSA UL: not formally set (intakes typically well-tolerated up to 3000 mg/day). Most adults exceed RDA from dietary sources (dairy, meat, fish, legumes, processed foods with phosphate additives); supplementation rarely needed in healthy individuals.
Safety notes
Phosphorus is generally well-tolerated in healthy individuals at intakes well above the RDA. Hyperphosphatemia is a major concern in chronic kidney disease (CKD) where renal phosphate excretion is impaired — supplementation and high-phosphorus diets must be avoided in CKD patients and require phosphate binder therapy. High phosphorus intake relative to calcium (Ca:P ratio significantly below 1:1) has been linked in observational studies to reduced bone mineral density and cardiovascular calcification; current Western diets often have a Ca:P ratio of ~1:2 due to phosphate food additives. Co-formulation with calcium is preferred when supplemental phosphorus is indicated; ANVISA IN 28/2018 requires Ca:P ratio between 1:1 and 2:1 for combined supplements. Drug interactions: aluminium / calcium / magnesium antacids reduce phosphate absorption; vitamin D enhances absorption. Pregnancy/lactation: dietary intake usually adequate.
Cross-market regulatory status
🇺🇸 FDA
United States (FDA): NO 21 CFR Part 101 Subpart E SSA health claim exists for phosphorus. Phosphorus is regulated as an essential mineral with an established RDI (1,250 mg per 21 CFR 101.9 for adults and children 4+ years). Manufacturers may use DSHEA structure/function claims for dietary supplements (e.g., "supports strong bones and teeth", "supports energy metabolism") provided they bear the FDA disclaimer ("This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.") and submit a 30-day notification to FDA per 21 USC 343(r)(6). Phosphorus appears in 21 CFR 101.72 only as a compositional condition on the calcium-and-osteoporosis SSA claim (calcium products bearing that claim cannot contain more phosphorus than calcium w/w), not as an independent phosphorus SSA claim. No phosphorus Qualified Health Claim (QHC) has been issued.
🇪🇺 EFSA
European Union (EFSA / Reg 432/2012): Four authorized Article 13(1) general-function health claims for phosphorus in the Annex to Commission Regulation (EU) No 432/2012 (CELEX:32012R0432) — normal energy-yielding metabolism, normal function of cell membranes, maintenance of normal bones, maintenance of normal teeth. All four share the standard condition: claim may be used only for food which is at least a source of phosphorus per the SOURCE OF reference in the Annex to Regulation (EC) No 1924/2006 (>=15% NRV per 100 g/100 mL or per portion; NRV = 700 mg per Regulation (EU) No 1169/2011 Annex XIII). EFSA NDA Panel underlying opinions: EFSA Journal 2009;7(9):1219 and 2010;8(10):1796. Character-level second-pass A/B framing confirmed Row 1 (energy-yielding metabolism) and Row 2 (cell membranes) use NO article "the" before "normal"; Rows 3 and 4 use "the maintenance of normal bones/teeth". No Article 14 reduction-of-disease-risk claim authorized for phosphorus.
🇧🇷 ANVISA
Brasil (ANVISA): Fósforo é constituinte autorizado para suplementos alimentares conforme Instrução Normativa IN nº 28/2018 (Anexos I/II/III/IV) e RDC 269/2005 (IDR adultos 700 mg). As alegações funcionais autorizadas (Anexo V) cobrem famílias consistentes com o escopo EFSA: metabolismo energético, função de membranas celulares, manutenção de ossos e dentes, todas iniciando com "O fósforo auxilia ...". Quando co-formulado com cálcio em um mesmo suplemento, a relação Ca:P deve estar entre 1:1 (mínimo) e 2:1 (máximo). Verbatim character-for-character requer consulta direta ao PDF oficial do BVSMS — authorized_claims ANVISA deste card intencionalmente ausentes até confirmação manual via leitura do PDF oficial.
Phosphorus and bone metabolism review · Ca:P ratio considerations and cola consumption controversy
Authorized claims · verbatim (4)
Direct quotes from each jurisdiction's framework · never paraphrased · with framework reference and conditions of use.
🇪🇺 EFSA · 4 claims
Reg 432/2012
Phosphorus contributes to normal energy-yielding metabolism
Conditions: The claim may be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006.
Reg 432/2012
Phosphorus contributes to normal function of cell membranes
Conditions: The claim may be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006.
Reg 432/2012
Phosphorus contributes to the maintenance of normal bones
Conditions: The claim may be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006.
Reg 432/2012
Phosphorus contributes to the maintenance of normal teeth
Conditions: The claim may be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006.
Common use cases
Adequate dietary nutritional support (most adults obtain from food)
Co-formulation with calcium for bone health (with appropriate Ca:P ratio)
Specific clinical use in hypophosphatemia (under medical supervision)
